DocGo Inc. (DCGO) Q4 2025 Earnings Call Transcript

DocGo held its Q4 and full-year 2025 earnings call on March 16, 2026 with CEO Lee Bienstock, CFO Norman Rosenberg and VP of IR Mike Cole participating alongside analysts from Deutsche Bank, Needham, BTIG, Cantor Fitzgerald and Stifel. The excerpt contains opening remarks and the standard forward-looking statements disclaimer and does not include any financial results, guidance, or material operational details.

Analysis

DocGo’s operating model has two underpriced optionalities that the market tends to miss: (1) route optimization and telehealth integration are high-leverage margin fixes — small utilization or routing efficiency gains (5–10% lift) translate into outsized EBITDA expansion because fixed vehicle and staffing costs scale poorly with idle hours; (2) longer-duration payor or municipal contracts materially raise revenue visibility and lower churn, turning what looks like a growth business into something closer to a recurring-services multiple. Expect realized margin expansion to lag initial commentary by 2–4 quarters as route software and scheduling changes require field retraining and vendor integration.

Key downside vectors are policy and payor risk: a single adverse reimbursement ruling or a municipal procurement loss can wipe out multiple quarters of expected EBITDA given concentrated contract sizes and unit economics tied to per-visit reimbursement. Regulatory enforcement (billing audits, EMS licensing) is a medium-term tail risk that can crystallize inside 3–9 months and materially increase working capital and compliance spend.

Competitive dynamics favor scale and data: larger incumbents or new private equity aggregators can undercut on price while cross-selling integrated telehealth; second-order effect — consolidation among smaller mobile providers would accelerate DocGo’s pricing power if it can convert technology wins into exclusive provider-of-record relationships. Watch cash conversion and capex cadence — capex step-ups to add vehicles/EMTs without commensurate utilization lifts are the most likely margin killers over the next 6–12 months.

Key Decisions for Investors

• Tactical long (size 1–2% NAV): Buy DCGO equity with a 6–12 month horizon. Rationale: fund incremental margin from routing/tech should compound into visible EBITDA in 2–4 quarters. Target +40–60% upside; hard stop at -25% to protect against contract loss or reimbursement shock.
• Defined-risk option spread (leverage without tail exposure): Buy a 12-month call spread (e.g., Jan 2027) with lower strike ~30% above current and upper strike ~90% above current. Cost should be <6% of underlying notional to deliver ~3:1 upside/downside if company executes on margin story.
• Relative-value pair (reduce macro/healthcare beta): Go long DCGO / short XHS (SPDR S&P Health Care Services ETF) equal notional for 3–9 months. This isolates execution on mobile services vs. broad health services volatility; trim if DCGO shows no utilization lift after two consecutive quarters.
• Downside protection (tail hedge): Buy 3–6 month out-of-the-money puts (~10–15% delta) to hedge event risk around near-term contract renewals or reimbursement announcements. Cost of puts is acceptable insurance vs. >50% drawdown risk from a lost large contract.